Technical analysis of Ligand Pharmaceuticals Incorporated (LGND): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions.
Price Performance
| 1 month | -4.31% |
| 3 months | +0.12% |
| Year-to-date | +45.55% |
| 1 year | +66.37% |
| 3 years | +339.90% |
| 5 years | +204.80% |
52-Week Range
| 52-week High | $326.63 |
| 52-week Low | $163.10 |
| Avg Volume (90d) | 310K |
Technical Indicators
| SMA 50 | $293.09 |
| SMA 200 | $235.17 |
| Beta | 1.00 |
| 30-day Volatility (annualised) | 20.8% |
| Price vs SMA 50 | -6.1% |
| Price vs SMA 200 | +17.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $191.31 | |
| 2025-11 | $203.18 | +6.2% |
| 2025-12 | $189.07 | -6.9% |
| 2026-01 | $192.10 | +1.6% |
| 2026-02 | $198.31 | +3.2% |
| 2026-03 | $199.65 | +0.7% |
| 2026-04 | $229.45 | +14.9% |
| 2026-05 | $231.96 | +1.1% |
| 2026-06 | $316.09 | +36.3% |
| 2026-07 | $287.54 | -9.0% |
| 2026-08 | $284.10 | -1.2% |
| 2026-09 | $275.20 | -3.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $284.47 |
| Market Cap | $5.7B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 27.49 |
| Price / Book | 5.71 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 1.17 |
| Current Ratio | 31.18 |